133 related articles for article (PubMed ID: 12439612)
1. Calcitonin-specific antitumor immunity in medullary thyroid carcinoma following dendritic cell vaccination.
Schott M; Feldkamp J; Klucken M; Kobbe G; Scherbaum WA; Seissler J
Cancer Immunol Immunother; 2002 Dec; 51(11-12):663-8. PubMed ID: 12439612
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy for medullary thyroid carcinoma by dendritic cell vaccination.
Schott M; Seissler J; Lettmann M; Fouxon V; Scherbaum WA; Feldkamp J
J Clin Endocrinol Metab; 2001 Oct; 86(10):4965-9. PubMed ID: 11600571
[TBL] [Abstract][Full Text] [Related]
3. Dendritic cell vaccination induces tumor epitope-specific Th1 immune response in medullary thyroid carcinoma.
Papewalis C; Wuttke M; Jacobs B; Domberg J; Willenberg H; Baehring T; Cupisti K; Raffel A; Chao L; Fenk R; Seissler J; Scherbaum WA; Schott M
Horm Metab Res; 2008 Feb; 40(2):108-16. PubMed ID: 18283628
[TBL] [Abstract][Full Text] [Related]
4. Pilot trial of autologous dendritic cells loaded with tumor lysate(s) from allogeneic tumor cell lines in patients with metastatic medullary thyroid carcinoma.
Bachleitner-Hofmann T; Friedl J; Hassler M; Hayden H; Dubsky P; Sachet M; Rieder E; Pfragner R; Brostjan C; Riss S; Niederle B; Gnant M; Stift A
Oncol Rep; 2009 Jun; 21(6):1585-92. PubMed ID: 19424640
[TBL] [Abstract][Full Text] [Related]
5. Amino acid-modified calcitonin immunization induces tumor epitope-specific immunity in a transgenic mouse model for medullary thyroid carcinoma.
Wuttke M; Papewalis C; Meyer Y; Kessler C; Jacobs B; Willenberg HS; Schinner S; Kouatchoua C; Baehring T; Scherbaum WA; Schott M
Endocrinology; 2008 Nov; 149(11):5627-34. PubMed ID: 18617610
[TBL] [Abstract][Full Text] [Related]
6. Dendritic cell vaccination in medullary thyroid carcinoma.
Stift A; Sachet M; Yagubian R; Bittermann C; Dubsky P; Brostjan C; Pfragner R; Niederle B; Jakesz R; Gnant M; Friedl J
Clin Cancer Res; 2004 May; 10(9):2944-53. PubMed ID: 15131029
[TBL] [Abstract][Full Text] [Related]
7. IFN-alpha skews monocytes into CD56+-expressing dendritic cells with potent functional activities in vitro and in vivo.
Papewalis C; Jacobs B; Wuttke M; Ullrich E; Baehring T; Fenk R; Willenberg HS; Schinner S; Cohnen M; Seissler J; Zacharowski K; Scherbaum WA; Schott M
J Immunol; 2008 Feb; 180(3):1462-70. PubMed ID: 18209041
[TBL] [Abstract][Full Text] [Related]
8. Heat shock treatment of tumor lysate-pulsed dendritic cells enhances their capacity to elicit antitumor T cell responses against medullary thyroid carcinoma.
Bachleitner-Hofmann T; Strohschneider M; Krieger P; Sachet M; Dubsky P; Hayden H; Schoppmann SF; Pfragner R; Gnant M; Friedl J; Stift A
J Clin Endocrinol Metab; 2006 Nov; 91(11):4571-7. PubMed ID: 16954161
[TBL] [Abstract][Full Text] [Related]
9. Dendritic cell vaccination with xenogenic polypeptide hormone induces tumor rejection in neuroendocrine cancer.
Papewalis C; Wuttke M; Seissler J; Meyer Y; Kessler C; Jacobs B; Ullrich E; Willenberg HS; Schinner S; Baehring T; Scherbaum WA; Schott M
Clin Cancer Res; 2008 Jul; 14(13):4298-305. PubMed ID: 18594013
[TBL] [Abstract][Full Text] [Related]
10. Medullary thyroid carcinoma: autologous tumor cell lines for dendritic cell vaccination.
Pfragner R; Skofitsch G; Höger H; Jech M; Rinner B; Siegl V; Niederle B; Gnant M; Friedl J; Stift A
Anticancer Res; 2005; 25(6B):4225-30. PubMed ID: 16309220
[TBL] [Abstract][Full Text] [Related]
11. HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities.
Santin AD; Bellone S; Palmieri M; Ravaggi A; Romani C; Tassi R; Roman JJ; Burnett A; Pecorelli S; Cannon MJ
Gynecol Oncol; 2006 Mar; 100(3):469-78. PubMed ID: 16249018
[TBL] [Abstract][Full Text] [Related]
12. Delayed-type hypersensitivity (DTH) immune response related with EBV-DNA in nasopharyngeal carcinoma treated with autologous dendritic cell vaccination after radiotherapy.
Li F; Song D; Lu Y; Zhu H; Chen Z; He X
J Immunother; 2013 Apr; 36(3):208-14. PubMed ID: 23502768
[TBL] [Abstract][Full Text] [Related]
13. alpha-fetoprotein and interleukin-18 gene-modified dendritic cells effectively stimulate specific type-1 CD4- and CD8-mediated T-Cell response from hepatocellular carcinoma patients in Vitro.
Cao DY; Yang JY; Dou KF; Ma LY; Teng ZH
Hum Immunol; 2007 May; 68(5):334-41. PubMed ID: 17462500
[TBL] [Abstract][Full Text] [Related]
14. Induction of a cellular and humoral immune response against preprocalcitonin by genetic i: a potential new treatment for medullary thyroid carcinoma.
Haupt K; Siegel F; Lu M; Yang D; Hilken G; Mann K; Roggendorf M; Saller B
Endocrinology; 2001 Mar; 142(3):1017-23. PubMed ID: 11181514
[TBL] [Abstract][Full Text] [Related]
15. Dendritic cell immunotherapy in a neuroendocrine pancreas carcinoma.
Schott M; Feldkamp J; Lettmann M; Simon D; Scherbaum WA; Seissler J
Clin Endocrinol (Oxf); 2001 Aug; 55(2):271-7. PubMed ID: 11531937
[TBL] [Abstract][Full Text] [Related]
16. Dendritic cell immunizations alone or combined with low doses of interleukin-2 induce specific immune responses in melanoma patients.
Escobar A; López M; Serrano A; Ramirez M; Pérez C; Aguirre A; González R; Alfaro J; Larrondo M; Fodor M; Ferrada C; Salazar-Onfray F
Clin Exp Immunol; 2005 Dec; 142(3):555-68. PubMed ID: 16297169
[TBL] [Abstract][Full Text] [Related]
17. Genetic immunotherapy for medullary thyroid carcinoma: destruction of tumors in mice by in vivo delivery of adenoviral vector transducing the murine interleukin-2 gene.
Zhang R; Baunoch D; DeGroot LJ
Thyroid; 1998 Dec; 8(12):1137-46. PubMed ID: 9920370
[TBL] [Abstract][Full Text] [Related]
18. Immunohistological analysis of peptide-induced delayed-type hypersensitivity in advanced melanoma patients treated with melanoma antigen-pulsed mature monocyte-derived dendritic cell vaccination.
Nakai N; Katoh N; Germeraad WT; Kishida T; Ueda E; Takenaka H; Mazda O; Kishimoto S
J Dermatol Sci; 2009 Jan; 53(1):40-7. PubMed ID: 18804963
[TBL] [Abstract][Full Text] [Related]
19. Vaccination with autologous tumour antigen-pulsed dendritic cells in advanced gynaecological malignancies: clinical and immunological evaluation of a phase I trial.
Hernando JJ; Park TW; Kübler K; Offergeld R; Schlebusch H; Bauknecht T
Cancer Immunol Immunother; 2002 Mar; 51(1):45-52. PubMed ID: 11845259
[TBL] [Abstract][Full Text] [Related]
20. Vaccination of patients with metastatic renal cell carcinoma with autologous dendritic cells pulsed with autologous tumor antigens in combination with interleukin-2: a phase 1 study.
Oosterwijk-Wakka JC; Tiemessen DM; Bleumer I; de Vries IJ; Jongmans W; Adema GJ; Debruyne FM; de Mulder PH; Oosterwijk E; Mulders PF
J Immunother; 2002; 25(6):500-8. PubMed ID: 12439347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
